familial hypercholesterolaemia
Cardiovascular · 2016–2024
6decisions
2medicines
4carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| evolocumab Treatment of homozygous familial hypercholesterolaemia (HoFH), heterozygous familial hypercholesterolaemia (HeFH) and non-familial hypercholesterolaemia… | Mar 2024 | Recommended with restriction | 1 individuals |
| inclisiran Amendment to restriction level for treatment of familial heterozygous hypercholesterolaemia (FHeH) and non-familial hypercholesterolaemia (non-FH) from… | Nov 2024 | Recommended with restriction | input received |
| evolocumab Treatment of homozygous familial hypercholesterolaemia (ho-FH), heterozygous FH (he-FH), and non-FH (in patients with atherosclerotic cardiovascular disease… | Mar 2021 | Recommended | none received |
| evolocumab Amendment to treatment criteria for evolocumab listings for homozygous familial hypercholesterolaemia, heterozygous familial hypercholesterolaemia, and… | Nov 2020 | Not recommended | input received |
| evolocumab Treatment of patients with Familial Hypercholesterolaemia (FH) and either symptomatic atherosclerotic cardiovascular disease (ASCVD) or FH with very high LDL-c. | Mar 2018 | Recommended with restriction | none received |
| evolocumab Treatment of familial hypercholesterolaemia (heterozygous and homozygous) in patients with established cardiovascular disease or homozygous disease, with LDL… | Mar 2016 | Recommended with restriction | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.